Results With TAFINLAR + MEKINIST

Proven clinical trial results

In a clinical trial, TAFINLAR® (dabrafenib) capsules + MEKINIST® (trametinib) tablets was studied in 2 different groups of people with the BRAF V600E genetic mutation: those taking TAFINLAR + MEKINIST as their first treatment and those previously treated before taking TAFINLAR + MEKINIST. 

Slows or shrinks tumors

In a clinical trial, TAFINLAR + MEKINIST was shown to help shrink or slow the growth of tumors in previously untreated and previously treated patients.

61% of 36 untreated patients achieved a response with TAFINLAR + MEKINIST

A total of 61% of 36 untreated patients achieved a response with TAFINLAR + MEKINIST. A total of 3% of untreated patients had a complete response and 58% had a partial response. As measured in a follow-up evaluation of the same trial, a total of 64% of untreated patients achieved a response with TAFINLAR + MEKINIST. A total of 6% of untreated patients had a complete response and 58% had a partial response.

For those previously treated before taking TAFINLAR + MEKINIST
63% of 57 previously treated patients achieved a response with TAFINLAR + MEKINIST

A total of 63% of 57 previously treated patients achieved a response with TAFINLAR + MEKINIST. Of these responders, 4% had a complete response and 60% of patients had a partial response.

6 of 10 responders had an antitumor response that was 6 months or longer with TAFINLAR + MEKINIST

For those taking TAFINLAR + MEKINIST as their first treatment

59% had a duration of response of 6 months or longer

During the initial trial evaluation, the median (or midpoint) duration of response for patients who have never been treated could not be determined. As measured in a follow-up evaluation of the same trial, the median duration of response for these patients was 15.2 months. This means that half of the patients who responded to treatment continued to respond longer than 15.2 months and half responded for less than 15.2 months. Of the 22 untreated patients who had a response with TAFINLAR + MEKINIST, 59% had a duration of response of 6 months or longer before their disease got worse.

For those previously treated before taking TAFINLAR + MEKINIST

64% had a duration response of 6 months or longer

The median (or midpoint) duration of response for patients who were previously treated was 12.6 months. This means that half of the patients who responded to treatment continued to respond longer than 12.6 months and half responded less than 12.6 months. Of the 36 previously treated patients who had a response with TAFINLAR + MEKINIST, 64% had a duration of response of 6 months or longer before their disease got worse.